Ascentage Pharma Group International
AAPG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002023311
No open-market purchases or sales by Ascentage Pharma Group International insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $263.5K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Ascentage Pharma Group International as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −1 vs. Q3 2025
- Shares held
- 47.8K
- −28.4K (−37.3%) vs. Q3 2025
- Total value
- $1.25M
- −$1.73M (−58.0%) vs. Q3 2025
- New holders
- 2
- 3 more added
- Sold out
- 3
- 5 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AAPG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $263.5K |
| Q1 2026 | 7 | $721.7K |
| Q4 2025 | 12 | $1.25M |
| Q3 2025 | 14 | $3.69M |
| Q2 2025 | 12 | $3.22M |
| Q1 2025 | 6 | $5.21M |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Ascentage Pharma Group International; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 16,726 | $438.9K | 0.00% | +16,726 | New |
| XY Capital Ltd | 13,628 | $357.6K | 0.36% | −4,492−24.8% | Reduced |
| Citadel Advisors LLC | 9,737 | $255.0K | 0.00% | +85+0.9% | Added |
| UBS Group AG | 4,232 | $111.0K | 0.00% | −14,113−76.9% | Reduced |
| Mirae Asset Global Investments Co., Ltd. | 2,546 | $66.8K | 0.00% | +83+3.4% | Added |
| Tower Research Capital LLC (TRC) | 230 | $6.04K | 0.00% | −599−72.3% | Reduced |
| Advisor Group Holdings, Inc. | 220 | $5.77K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 201 | $5.27K | 0.00% | +21+11.7% | Added |
| Morgan Stanley | 153 | $4.01K | 0.00% | −50−24.6% | Reduced |
| Bell Investment Advisors, Inc | 67 | $1.76K | 0.00% | 00.0% | Unchanged |
| EverSource Wealth Advisors, LLC | 24 | $630 | 0.00% | −43−64.2% | Reduced |
| Royal Bank of Canada | 6 | $0 | 0.00% | +6 | New |
| NEOS Investment Management LLC | 0 | $0 | 0.00% | −10,385−100.0% | Sold out |
| Tema ETFs LLC | 0 | $0 | 0.00% | −10,385−100.0% | Sold out |
| Abc Arbitrage SA | 0 | $0 | 0.00% | −5,230−100.0% | Sold out |
| Point72 (DIFC) Ltd | – | – | – | – | Not filed |